Neurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA(TM) (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia
SAN DIEGO, Nov. 29, 2016 -- (Healthcare Sales & Marketing Network) -- Neurocrine Biosciences, Inc. (NBIX) today announced that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data included in the... Biopharmaceuticals, Neurology, FDA Neurocrine Biosciences, INGREZZA, valbenazine, tardive dyskinesia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Brain | Dyskinesia | Food and Drug Administration (FDA) | Marketing | Neurology | New Drug Applications | Pharmaceuticals